Condition (MeSH)
Vaccinia
ClinicalTrials.gov lists 53 trials for Vaccinia or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 16.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
53 of the 53 trials are tagged with Vaccinia itself; the rest are tagged with a narrower condition beneath it.
When did Vaccinia trials start? (18)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 4 |
| 2022 | 3 |
| 2021 | 1 |
| 2019 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2012 | 3 |
Showing 10 of 18 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 34 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 25 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Vaccinia trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 28 |
| Phase 1/2 | 5 |
| Phase 2 | 7 |
| Phase 3 | 4 |
| Not applicable | 1 |
| Observational | 8 |
How many Vaccinia trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Active, not recruiting | 1 |
| Completed | 41 |
| Terminated | 1 |
| Withdrawn | 2 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Vaccinia trials? (11)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 16 |
| Jennerex Biotherapeutics | 7 |
| Emergent BioSolutions | 4 |
| Genelux Corporation | 4 |
| Genelux GmbH | 2 |
Showing 5 of 11 sponsors.
Which drugs are being tested for Vaccinia? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| GL-ONC1 | 5 |
| JX-594 | 4 |
| Smallpox Vaccine | 2 |
| Sorafenib | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| gp160 Vaccine (Immuno-AG) | 13 |
| HIVAC-1e | 6 |
| Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594) | 3 |
| hepatitis B vaccines | 2 |
| rgp120/HIV-1 SF-2 | 2 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Vaccinia trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pyrexia | 40 | 5 |
| Diarrhoea | 36 | 4 |
| Hepatic failure | 31 | 4 |
| Respiratory failure | 28 | 3 |
| Abdominal pain | 27 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Vaccinia? (26)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The association between BCG scars and self-reported chronic diseases: A cross-sectional observational study within an RCT of Danish health care workers. | Vaccine | 2024 | Yes |
| Monkeypox. | Lancet (London, England) | 2023 | Yes |
| One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines. | The Journal of infectious diseases | 2023 | Yes |
| Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. | JAMA oncology | 2023 | Yes |
| Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus-specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis. | American journal of hematology | 2023 | Yes |
Showing 5 of 26 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.